NASDAQ$ALXO
ALX Oncology Holdings Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
ALX Oncology reported Q2 2025, net income of $25.95B.
For Q2 2025, ALX Oncology reported net income of $25.95B. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Net income $25.95B.
- ALX Oncology highlights operating priorities and capital allocation.
- ALX Oncology highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
ALX Oncology · Revenue · Quarterly
$0
Forward guidance
The release discusses ALX Oncology's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- ALX Oncology cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.7%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+26.0%
Q4 2024
Best reaction
-21.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -10.2% | -6.8% | -13.2% | |
| Q3 2025 | +15.5% | +8.5% | +20.3% | |
| Q2 2025 | +7.4% | +57.9% | +72.4% | |
| Q1 2025 | -8.2% | -0.2% | +25.9% | |
| Q4 2024 | +26.0% | -6.4% | -50.4% | |
| Q3 2024 | -5.2% | -12.4% | +5.9% | |
| Q1 2024 | -2.4% | -8.7% | -45.8% | |
| Q4 2023 | +3.0% | -16.2% | -17.2% | |
| Q3 2023 | +13.2% | +21.8% | +70.5% | |
| Q2 2023 | +1.4% | -2.6% | -1.4% | |
| Q1 2023 | +0.6% | -7.0% | +23.3% | |
| Q4 2022 | -13.6% | -15.9% | -28.7% | |
| Q3 2022 | -1.8% | +1.1% | -14.2% | |
| Q2 2022 | +2.6% | +26.6% | +5.6% | |
| Q1 2022 | -6.8% | -8.1% | -24.1% | |
| Q4 2021 | +7.7% | -1.3% | +2.7% | |
| Q3 2021 | +8.8% | +6.3% | -26.4% | |
| Q2 2021 | +0.6% | +2.1% | +16.6% | |
| Q1 2021 | -1.1% | -1.6% | +7.3% | |
| Q4 2020 | -21.9% | -19.4% | -24.8% | |
| Q3 2020 | +4.2% | +34.6% | +65.1% | |
| Q2 2020 | +2.0% | -3.8% | -10.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro